SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
May 17, 2017
Commission File Number: 0-29374
EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin - France
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ x] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 17, 2017
EDAP TMS S.A.
/s/ FRANCOIS DIETSCH
CHIEF FINANCIAL OFFICER
EDAP TMS SA Reports 1Q 2017 Results
LYON, France, May 17, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today financial results for the first quarter ended March 31, 2017, and provided an update on strategic and operational accomplishments.
"Our first quarter revenues remain in line with our revenues from first quarter 2016", said Marc Oczachowski, EDAP's Chief Executive Officer. "We continue to expand our education efforts in the U.S. as demonstrated by our successful addition of more than 50 new urologists to our HIFU training program during the first quarter. As a result, momentum in the U.S. continues as evidenced by the significant growth of our pipeline of HIFU projects. Global HIFU treatment driven revenue continues to increase with 16.5% growth year over year, while our global UDS/Lithotripsy business grew 16.5% compared to the first quarter of 2016."
Marc Oczachowski added: "We are well positioned to continue with our strategic initiatives to ensure a solid foundation for growth in the U.S. market. In late February 2017, we submitted our dossier for reimbursement to CMS Medicare for C-code allocation; we expect feedback from CMS no later than July 2017. We have also expanded our HIFU product offerings with the addition of our Ablatherm Fusion device, announced during the American Urological Association's annual conference in Boston last week-end."
First Quarter 2017 Results
Total revenue for the first quarter 2017 was EUR 8.7 million (USD 9.3 million), a 0.6% decreased compared to EUR 8.7 million (USD 9.6 million) for the first quarter of 2016.
For the three months ended March 31, 2017, total revenue for the Lithotripsy division was EUR 6.4 million (USD 6.8 million), a 16.5% increase compared to EUR 5.5 million (USD 6.0 million) during the year-ago period.
Total revenue in the HIFU business for the first quarter was EUR 2.3 million (USD 2.5 million), a 29.1% decrease compared to EUR 3.3 million (USD 3.6 million) for the first quarter of 2016.
Gross profit for the first quarter 2017 was EUR 3.6 million (USD 3.8 million), compared to EUR 4.3 million (USD 4.7 million) for the year-ago period. Gross profit margin on net sales was 41.1% in the first quarter of 2017, compared to 49.2% in the prior year period.
Operating loss for the first quarter 2017 was EUR 0.4 million (USD 0.4 million), compared to an operating profit of EUR 0.7 million (USD 0.8 million) in the first quarter of 2016.
Net income for the first quarter 2017 was EUR 1.7 million (USD 1.8 million), or earnings of EUR 0.06 per diluted share, as compared to net income of EUR 1.4 million (USD 1.5 million), or earnings of EUR 0.05 per diluted share in the year-ago period. Net income in the first quarter of 2017 included non-cash interest income of EUR 2.0 million (USD 2.1 million) to adjust the accounting fair value of the outstanding warrants.
An accompanying conference call will be conducted by Philippe Chauveau, Chairman of the Board; Marc Oczachowski, Chief Executive Officer; and Francois Dietsch, Chief Financial Officer, to go over the results. The call will be held at 8:30 AM ET, on Thursday, May 18, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
May 18, 2017, 8:30 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: EDAP-TMS First Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website,www.edap-tms.com under "Investors Information."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. Ablatherm Fusion is not FDA cleared yet. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.
In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
EDAP TMS S.A.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
|Three months ended:||Three months ended:|
|Mar. 31,||Mar. 31,||Mar. 31,||Mar. 31,|
|Sales of medical equipment||5,512||5,999||5,899||6,617|
|Net Sales of RPP and Leases||1,295||1,262||1,386||1,392|
|Sales of spare parts, supplies and Services||1,842||1,467||1,972||1,618|
|TOTAL NET SALES||8,648||8,728||9,257||9,627|
|Cost of sales||(5,123||)||(4,436||)||(5,483||)||(4,893||)|
|Research & development expenses||(896||)||(814||)||(959||)||(898||)|
|S, G & A expenses||(3,075||)||(2,745||)||(3,291||)||(3,028||)|
|Total operating expenses||(3,971||)||(3,559||)||(4,250||)||(3,926||)|
|OPERATING PROFIT (LOSS)||(419||)||733||(449||)||808|
|Interest (expense) income, net||1,983||479||2,123||528|
|Currency exchange gains (loss), net||175||188||188||207|
|Other income (loss), net||-||-||-||-|
|INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST||1,739||1,400||1,861||1,544|
|Income tax (expense) credit||(58||)||(39||)||(62||)||(43||)|
|NET INCOME (LOSS)||1,681||1,360||1,799||1,501|
|Earning per share – Basic||0.06||0.05||0.06||0.06|
|Average number of shares used in computation of EPS||28,839,099||25,400,445||28,839,099||25,400,445|
|Earning per share – Diluted||0.06||0.05||0.06||0.06|
|Average number of shares used in computation of EPS for positive net||30,213,544||26,987,182||30,213,544||26,987,182|
NOTE: Translated for convenience of the reader to U.S. dollars at the 2017 average three months’ noon buying rate of 1 Euro = 1.0703 USD, and 2016 average three months’ noon buying rate of 1 Euro = 1.1030 USD.
EDAP TMS S.A.
CONDENSED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS
(amounts in thousands of Euros and U.S. Dollars)
|Cash, cash equivalents and short term investments||20,321||21,989||21,739||23,202|
|Total current assets||40,542||40,514||43,370||42,750|
|Total current liabilities||14,052||15,010||15,032||15,838|
NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.0697 USD, on March 31, 2017 and at the noon buying rate of 1 Euro = 1.0552 USD, on December 31, 2016.
EDAP TMS S.A.
CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
THREE MONTHS ENDED MARCH 31,2017
(Amounts in thousands of Euros)
|HIFU Division||UDS Division||Corporate||
|Sales of goods||1,048||4,464||5,512|
|Sales of RPPs & Leases||958||336||1,295|
|Sales of spare parts & services||317||1,525||1,842|
|TOTAL NET SALES||2,323||6,325||8,648|
|(% of Total Revenues)|
|Research & Development||(579||)||(317||)||(896||)|
|Total SG&A plus depreciation||(1,112||)||(1,596||)||(366||)||(3,075||)|
|OPERATING PROFIT (LOSS)||(465||)||411||(366||)||(419||)|